Drug Profile
Puquitinib
Alternative Names: Puquitinib mesylateLatest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Zhejiang Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Cancer in China (PO, Tablet)
- 06 Apr 2011 Phase-I development in Cancer is ongoing in China
- 06 Apr 2011 Pharmacodynamics data from a preclinical trial in Cancer presented at the 102nd Annual Meeting of the American Association for Cancer Research (102nd-AACR-2011)